Oral Anticoagulation in Hemodialysis

• Status: Completed
• Trial end date: 2020-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigators refer to the trial with clinicaltrials.gov indentifier NCT02610933 entitled Effect on Vascular Calcification of Replacing Warfarin by Rivaroxaban With or Without VitK2 in Hemodialysis Patients.

After termination of this trial, included patients will be asked to participate in the extension trial by continuing the treament of their respective allocation arm. No new intervention will be done.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Onze Lieve Vrouw Hospital
• Treatments: Rivaroxaban; Vitamin K; Vitamin K 2; Vitamin MK 7; Vitamins; Warfarin

Criteria

Inclusion Criteria:

• inclusion in the trial with clinicaltrials.gov identifier NCT02610933

• signed informed consent for this extension trial

Exclusion Criteria:

• none